The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed.
Phase I
9605: Phase I Study of Ganetespib and Ziv-Aflibercept in Patients with Advanced Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas. National Cancer Institute Developmental Therapeutics Clinic; Kummar, Shivaani. (301) 435-0517
AMC-091: Phase I and Pharmacokinetic Study of Ibrutinib in HIV-Infected Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Multiple Myeloma. AIDS-Associated Malignancies Clinical Trials Consortium; Kasamon, Yvette L. (410) 955-8839
Phase II
AOST1322: A Phase II Study of Eribulin (IND# 122686, NSC# 707389) in Recurrent or Refractory Osteosarcoma. Children’s Oncology Group; Isakoff, Michael Scott. (860) 545-9630
Phase III
A081105: Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC). Alliance for Clinical Trials in Oncology; Govindan, Ramaswamy. (314) 362-5737
A221304: A Phase III Placebo-Controlled, Randomized Three-Arm Study of Doxepin and a Topical Rinse in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy. Alliance for Clinical Trials in Oncology; Miller, Robert C. (507) 284-2669
NRG-GI001: Randomized Phase III Study of Focal Radiation Therapy for Unresectable, Localized Intrahepatic Cholangiocarcinoma. NRG Oncology; Hong, Theodore Sunki. (617) 726-5866
Pilot Phase
9671: Exceptional Responders Pilot Study: Molecular Profiling of Tumors From Cancer Patients Who Are Exceptional Responders. National Institutes of Health; Conley, Barbara A. (240) 276-6505
WFU-01213: Reducing Lung Cancer Survivors’ Anxiety and Dyspnea (RELAX). Wake Forest Cancer Center CCOP Research Base; Danhauer, Suzanne C. (336) 716-7980
Other Phases
A151308: Genetic Contributions to Symptom Reports: A Proposed Pilot Project. Alliance for Clinical Trials in Oncology; Sloan, Jeff A. (507) 284-9985
AALL14B5-Q: Identification of High Risk AIEOP Childhood ALL Cases with Targetable Fusion Transcripts. Children’s Oncology Group; Cazzaniga, Giovanni. 39-0-39-233.2288.3661
ABTR14B2-Q: DDX3, A Novel Therapeutic Target in Sarcoma Ewing, Osteo and Rhabdomyosarcoma. Children’s Oncology Group; Loeb, David M. (410) 502-7247
NRG-BN-TS002: Prognostic and Predictive Markers in Low-Grade Gliomas: A Study Based on RTOG 9802. NRG Oncology; Chakravarti, Arnab. (614) 293-3241
